Telomir Pharmaceuticals completes acquisition of TELI, consolidating global rights to Telomir-1

Telomir Pharmaceuticals, Inc.

Acquired 100% of TELI for 34,389,710 restricted shares of Telomir common stock to former TELI shareholders.
Bayshore Trust contributed $1 million at closing and has an option to provide up to $4 million upon IND acceptance and Phase 1/2 study start.
Option includes $2 million for 1,492,537 shares at $1.34 per share upon FDA IND acceptance, and another $2 million for the same number of shares upon Phase 1/2 initiation.
Transaction eliminates prior geographic fragmentation, giving Telomir full worldwide control of Telomir-1 development and commercialization.

item 1.01item 2.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.